PureTech Announces Board Change
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces that Raju Kucherlapati, PhD, has stepped down from his role as a member and Chair of the Board of Directors.
'Raju has been an integral part of PureTech's journey for almost two decades, and we are deeply grateful for his dedication and leadership,' said Bharatt Chowrira, PhD, JD, PureTech's Chief Executive Officer. 'On behalf of the board, I'd like to wish Raju all the best in his future endeavors.'
PureTech has appointed Sharon Barber-Lui, PureTech's Audit Committee Chair, as Interim Chair of the Board of Directors. In collaboration with the Nominating Committee, Ms. Barber-Lui will lead the process to identify a new Chair of the Board of Directors and will engage with shareholders to gather input on the criteria and overall board evolution as part of the process.
Robert Langer, ScD, PureTech's Co-founder and member of the board said, 'Raju is a unique individual, an amazing scientist, and a great friend and mentor to so many people in the biotech industry. It has been an honor and a privilege to serve alongside Raju for so many years at PureTech. I speak for the entire board in thanking him for his many years of dedication and his outstanding contributions.'
During his tenure on the board, Dr. Kucherlapati helped guide PureTech from its startup phase into an established biotherapeutics company, which has an industry-leading track record of advancing breakthrough medicines, such as the recently FDA-approved Cobenfy™, and launching innovative Founded Entities, most recently, Seaport Therapeutics.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.
For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to our expectations around our therapeutic candidates and approach towards addressing major diseases, our intention to initiate a process to identify a new Chair of the Board of Directors, our future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption 'Risk Factors' in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.View source version on businesswire.com:https://www.businesswire.com/news/home/20250708508613/en/
CONTACT: PureTech
Investor Relations
[email protected]
KEYWORD: EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH OTHER HEALTH
SOURCE: PureTech Health plc
Copyright Business Wire 2025.
PUB: 07/08/2025 12:45 PM/DISC: 07/08/2025 12:46 PM
http://www.businesswire.com/news/home/20250708508613/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Meta Platforms, Inc. (META): Jim Cramer Wants Smartglasses To Translate Language
We recently published . Meta Platforms, Inc. (NASDAQ:META) is one of the stocks Jim Cramer recently discussed. Meta Platforms, Inc. (NASDAQ:META)'s shares have gained 21% year-to-date and made it one of the top-performing big tech stocks in 2025. Cramer's previous comments about the firm have pointed out that it has a low earnings multiple despite the 2025 share price gains. He has also attributed Meta Platforms, Inc. (NASDAQ:META)'s performance to its advertising business and strong cost-cutting efforts. However, the CNBC TV host does not believe that the firm is executing well in its AI business. Here are his recent thoughts about Meta Platforms, Inc. (NASDAQ:META), which discussed the firm taking a minority stake in eyewear company Luxottica: '[On a minority stake in Luxottica to boost the metaverse] Well he had it before, remember when I was out with the Luxottica people out in the Hamptons, actually Montauk that's David's area and there was a party there to celebrate the fact that, that they got this deal. I bought the glasses, my most recent doesn't have, it doesn't have the language capacity. Maybe I can downgrade it didn't have it when I was in Belgium, I said tell me this in, give me something in Dutch and it's like sorry I don't speak that. Which was a bummer. But I bought them.' Cramer recently discussed Meta Platforms, Inc. (NASDAQ:META)'s valuation multiple. Here's what he said: 'Meta still has a low multiple. Meta's recreating and. . .remediating the entire advertising business. Along with Amazon and along with YouTube. And Meta's the leader.' While we acknowledge the potential of META as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
an hour ago
- Yahoo
Datadog, Inc. (DDOG) Is Competing With The Rise Of AI, Says Jim Cramer
We recently published . Datadog, Inc. (NASDAQ:DDOG) is one of the stocks Jim Cramer recently discussed. Datadog, Inc. (NASDAQ:DDOG) is a software company that works primarily with cloud computing providers and users. The firm's products allow customers to monitor their platforms in real-time. Datadog, Inc. (NASDAQ:DDOG)'s shares have lost 4% year-to-date, primarily on the back of an 11% dip in July. The shares have lost ground this month because of a downgrade from Guggenheim, which reduced the rating to Sell from Neutral and set a $105 share price target for the company. Cramer discussed how AI has harmed Datadog, Inc. (NASDAQ:DDOG): '[On Morgan Stanley saying Tim Cook's successor could benefit from having a hardware background] Well look, it's funny hardware is part of the, I'm glad you mentioned hardware, hardware's part of the issue of how NVIDIA got to where it is. This is an essentially, there's a belief in many people on Wall Street and in Silicon Valley, that hardware prevails here because we're gonna get rid of a huge number of people who would do SaaS, you know, software as a service, and that includes, yes, Salesforce, includes ServiceNow, includes DataDog which got out of the S&P. Because there are going to be fewer and fewer people who are actually in the organization who need that.' A close-up of a laptop with a software engineer coding on the monitor. Baron Funds mentioned Datadog, Inc. (NASDAQ:DDOG) in its Q1 2025 investor letter. Here is what the fund said: 'Most of our companies do not sell goods but instead provide critical services to their Inc. (NASDAQ:DDOG), the leading cloud-based observability platform, has seen its stock decline by over 30% year-to-date because its revenues are based on consumption/usage and would likely be impacted by any significant cyclical downturn. However, its competitive position has gotten stronger, its market share is continuing to rise, and it is indexed to promising long-term secular trends of cloud adoption and accelerating app development, and is well positioned for AI as the critical central IT infrastructure platform for its customers.' While we acknowledge the potential of DDOG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
CoreWeave, Inc. (CRWV) Is Confident About NVIDIA's AI GPU Demand, Says Jim Cramer
We recently published . CoreWeave, Inc. (NASDAQ:CRWV) is one of the stocks Jim Cramer recently discussed. CoreWeave, Inc. (NASDAQ:CRWV) is an AI and cloud computing infrastructure provider. It is one of the strongest-performing stocks of 2025 as the shares have gained 226% since their IPO in March. CoreWeave, Inc. (NASDAQ:CRWV) has benefited from market optimism about AI as investors believe that the firm can benefit from sustained long-term AI demand and its early mover advantage in the AI infrastructure space. CoreWeave, Inc. (NASDAQ:CRWV) also recently announced that it would acquire Core Scientific, and Cramer commented that the deal made him optimistic about the overall dealmaking environment in America. Here are his recent remarks about CoreWeave, Inc. (NASDAQ:CRWV): 'You speak to CoreWeave, you speak to Michael Entrator, who's a terrific guy. Uh, he would say look, we can't put 'em up fast enough. And, we are, they're valuable even after they do not have the latest and greatest. People do not understand that. This is not the 386 going to the 46 going to the Pentium, you can't throw these away. They work. There's always some use for even the oldest ones. So they pay themselves back.' In his earlier remarks, Cramer commented on CoreWeave, Inc. (NASDAQ:CRWV)'s latest deal and his meetings with management: 'Yes and they're all over me today. CoreWeave is saying that this helps them immensely in terms of the amount of power they have and it's actually a good deal for their finances. The stock's turned up, they were up big on, well CoreWeave was up big, and it's given back that. This is the kind of deal that if I were Lina Khan at the FTC, I would say wait a second, Core and Core? No. We will not let a core merge with a core. . . No I mean to being facetious, but not really, in someways because I think she would say these are two companies that could compete. Which is true. But I think that this is the kind of deal that we ought to get used to having. It's one of the things that makes me bullish. Which is that there's not any, you know you can make a deal if you think it's rational and not expect to be challenged. Now someone might say, you know Jim, that was really a cheap shot. No. The deference was cheap. The deference. 'I've got Michael Entrator. He has done a remarkable job, I don't know if people care about CoreWeave anymore, but, Michael Entrator's stock opened, it was at 40 and it went up to 156! You know, did people who buy that make money or did they just kind of say you know what, I'm glad I have my index fund but by the way, no. Ben Stoto and I were very positive on CoreWeave after meeting with the company and spending some time with them. Just very impressive people who were doubted and are doubted, there's a very big short position. But you know what, they figured they have a, when you ask NVIDIA what do you think of them, and NVIDIA bought a quarter of that IPO, NVIDIA would say great partner, great partner. While we acknowledge the potential of CRWV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
